[Motor and cognitive functions of the neostriatum during bilateral blocking of its dopamine receptors].
In experiments on 60 Sprague-Dawley rats, effects of systemic and intrastriatal injections of se-lective blocker of D1 receptors SCH23390 on elaboration of discriminational conditioned reflex of active avoidance (CRAA) were studied in T-maze and on behavior in test of the "open field". Systemic administration of this inhibitor at doses of 0.025 mg/kg produced a several fold decrease of percentage of correct realizations of the discriminational CRAA and of motor activity in the "open field" test. Bilateral microinjections of SCH23390 into the rat neostriatum at a dose of 0.004-1.0 mkg did not deteriorate learning of the discriminational CRAA as compared with intact control, although a marked inhibition of motor activity was observed in the open field, test. Analysis of the data has also shown a statistically significant decrease of percentage of errors in the starting maze compartment in experiments with intrastriatal injection of SCH23390 to rats. At the same time, the intrastriatal injection to rats of raclopride, a blocker of D2 dopamine receptors, at a dose of 0.004 mkg produced a sharp and prolonged deterioration of learning of the discriminational CRAA. The data obtained have allowed the following conclusions to be made: 1. Difference of effects of the systemic and intrastriatal SCH23390 injections seems to be due to that the behavioral changes observed at the systemic administration can be provided predominanantly by structures differing from neostriatal D1 receptors; 2. Effect of nigrostriatal dopaminergic system on the neostriatum through D1 receptors is complex: activation of motor activity (efferent spine cells of the direct pathway) and a poor modulation of the learning process (large aspine cholinergic interneurons); 3. The modulation of the learning process seems to occur through neostriatal D2 receptors (large aspine cholinergic interneurons).
Shapovalova
K B
KB
Kamkina
Iu V
IuV
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology*; D001552:Benzazepines / Q000494:pharmacology; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology*; D065127:Dopamine D2 Receptor Antagonists; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D017072:Neostriatum / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*
D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2